JP2015504847A - 前立腺癌骨転移および薬剤耐性肺癌を治療するためのマイクロｒｎａｍｉｒ−４０９−５ｐ、ｍｉｒ−３７９、およびｍｉｒ−１５４＊の標的化 - Google Patents

前立腺癌骨転移および薬剤耐性肺癌を治療するためのマイクロｒｎａｍｉｒ−４０９−５ｐ、ｍｉｒ−３７９、およびｍｉｒ−１５４＊の標的化 Download PDF

Info

Publication number
JP2015504847A
JP2015504847A JP2014544946A JP2014544946A JP2015504847A JP 2015504847 A JP2015504847 A JP 2015504847A JP 2014544946 A JP2014544946 A JP 2014544946A JP 2014544946 A JP2014544946 A JP 2014544946A JP 2015504847 A JP2015504847 A JP 2015504847A
Authority
JP
Japan
Prior art keywords
mir
cancer
seq
metastatic
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014544946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504847A5 (enExample
Inventor
リーランド ダブリュ． ケイ． チュン
リーランド ダブリュ． ケイ． チュン
サジニ ジョッソン
サジニ ジョッソン
ムラリ グルラジャン
ムラリ グルラジャン
アンジャリ ジェイン
アンジャリ ジェイン
Original Assignee
シーダーズ−サイナイ メディカル センター
シーダーズ−サイナイ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーダーズ−サイナイ メディカル センター, シーダーズ−サイナイ メディカル センター filed Critical シーダーズ−サイナイ メディカル センター
Publication of JP2015504847A publication Critical patent/JP2015504847A/ja
Publication of JP2015504847A5 publication Critical patent/JP2015504847A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
JP2014544946A 2011-11-30 2012-11-30 前立腺癌骨転移および薬剤耐性肺癌を治療するためのマイクロｒｎａｍｉｒ−４０９−５ｐ、ｍｉｒ−３７９、およびｍｉｒ−１５４＊の標的化 Pending JP2015504847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161565226P 2011-11-30 2011-11-30
US61/565,226 2011-11-30
PCT/US2012/067403 WO2013082499A1 (en) 2011-11-30 2012-11-30 Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer

Publications (2)

Publication Number Publication Date
JP2015504847A true JP2015504847A (ja) 2015-02-16
JP2015504847A5 JP2015504847A5 (enExample) 2016-01-14

Family

ID=48536124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014544946A Pending JP2015504847A (ja) 2011-11-30 2012-11-30 前立腺癌骨転移および薬剤耐性肺癌を治療するためのマイクロｒｎａｍｉｒ−４０９−５ｐ、ｍｉｒ−３７９、およびｍｉｒ−１５４＊の標的化

Country Status (6)

Country Link
US (1) US20140323551A1 (enExample)
EP (2) EP3106168A3 (enExample)
JP (1) JP2015504847A (enExample)
CN (1) CN104080461A (enExample)
AU (1) AU2012345666A1 (enExample)
WO (1) WO2013082499A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016508148A (ja) * 2013-01-07 2016-03-17 エーアールオージー ファーマスーティカルズ，インクＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 変異ｆｌｔ３増殖性障害の治療剤クレノラニブ（ｃｒｅｎｏｌａｎｉｂ）
US9745578B2 (en) 2011-11-30 2017-08-29 Cedars-Sinai Medical Center Targeting microRNA miR-409-3P to treat prostate cancer
KR20190022310A (ko) 2017-08-25 2019-03-06 삼성전자주식회사 전고체형 이차전지
US10854877B2 (en) 2017-08-25 2020-12-01 Samsung Electronics Co., Ltd. All-solid-state secondary battery
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US12319913B2 (en) 2018-10-31 2025-06-03 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10801071B2 (en) * 2014-04-22 2020-10-13 The Johns Hopkins University TGF(β)-MIR200-MIG6 pathway and its use in the treatment of cancer as an indicator of resistance to EGFR inhibitors
US10493165B2 (en) 2015-01-30 2019-12-03 The Johns Hopkins University Extracellular vesicles for agent delivery
US10870852B2 (en) 2015-10-06 2020-12-22 University Of Virginia Patent Foundation Compositions and methods for treating diabetic retinopathy
US20190269801A1 (en) 2016-10-21 2019-09-05 Cedars-Sinai Medical Center Simvastatin and chemotherapeutic conjugates with a heptamethine carbocyanine dye resensitize human tumors to hormonal antagonists and chemotherapy
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
CN107488734B (zh) * 2017-10-10 2019-11-05 广州医科大学附属第二医院 miR-19a-3p在制备前列腺癌骨转移诊断试剂和治疗药物中的应用
CN107630092B (zh) * 2017-10-23 2020-03-31 广州医科大学附属第二医院 miR-505-3p应用于前列腺癌骨转移的诊断、预后和治疗
CN108148911B (zh) * 2018-03-02 2019-11-05 广州医科大学附属第二医院 miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用
KR102132222B1 (ko) * 2018-11-27 2020-07-09 강원대학교산학협력단 항암제 내성 진단 마커로서의 miR-143-3p 및 miR-373-5p, 및 이의 이용
CN110305863B (zh) * 2019-06-10 2020-12-08 浙江大学 用于上调人DLK1-DIO3印记域非编码RNA表达的sgRNA、重组质粒和细胞株
CN110819718B (zh) * 2019-12-16 2023-05-26 广州医科大学附属第二医院 miR-154-5p在前列腺癌骨转移的新应用
JP2023521356A (ja) * 2020-04-07 2023-05-24 アドヴァンスド セル ダイアグノスティクス，インコーポレイテッド ｉｎ ｓｉｔｕハイブリダイゼーションによって標的核酸を検出する方法及びそのキット

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519606A (ja) * 2004-11-12 2008-06-12 アンビオン インコーポレーティッド ｍｉＲＮＡおよびｍｉＲＮＡ阻害分子に関する方法および組成物
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
CN102080085A (zh) * 2009-12-01 2011-06-01 中国科学院上海药物研究所 人miR-193b反义核酸及其应用
WO2011076142A1 (en) * 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of colorectal cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1784501B1 (en) * 2004-05-14 2015-11-18 Rosetta Genomics Ltd VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
US20060265771A1 (en) * 2005-05-17 2006-11-23 Lewis David L Monitoring microrna expression and function
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
JP5489459B2 (ja) * 2005-08-01 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物
CN101627121A (zh) * 2006-12-08 2010-01-13 奥斯瑞根公司 作为治疗干预的靶标的miRNA调控基因和路径
US20080311040A1 (en) * 2007-03-06 2008-12-18 Flagship Ventures METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA
PL2623598T3 (pl) * 2007-10-04 2018-12-31 Roche Innovation Center Copenhagen A/S Micromir
ES2600165T3 (es) * 2008-02-28 2017-02-07 The Ohio State University Research Foundation Antagonistas de miR-32 para aumentar la respuesta del cáncer de próstata a la apoptosis
AU2010249421A1 (en) * 2009-05-22 2011-12-08 Asuragen, Inc. miRNA biomarkers of prostate disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519606A (ja) * 2004-11-12 2008-06-12 アンビオン インコーポレーティッド ｍｉＲＮＡおよびｍｉＲＮＡ阻害分子に関する方法および組成物
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
CN102080085A (zh) * 2009-12-01 2011-06-01 中国科学院上海药物研究所 人miR-193b反义核酸及其应用
WO2011076142A1 (en) * 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of colorectal cancer

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745578B2 (en) 2011-11-30 2017-08-29 Cedars-Sinai Medical Center Targeting microRNA miR-409-3P to treat prostate cancer
JP2016508148A (ja) * 2013-01-07 2016-03-17 エーアールオージー ファーマスーティカルズ，インクＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 変異ｆｌｔ３増殖性障害の治療剤クレノラニブ（ｃｒｅｎｏｌａｎｉｂ）
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US12371693B2 (en) 2016-11-01 2025-07-29 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
KR20190022310A (ko) 2017-08-25 2019-03-06 삼성전자주식회사 전고체형 이차전지
US10854877B2 (en) 2017-08-25 2020-12-01 Samsung Electronics Co., Ltd. All-solid-state secondary battery
US12319913B2 (en) 2018-10-31 2025-06-03 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer

Also Published As

Publication number Publication date
CN104080461A (zh) 2014-10-01
AU2012345666A1 (en) 2014-06-19
WO2013082499A1 (en) 2013-06-06
EP3106168A2 (en) 2016-12-21
EP2785355A4 (en) 2015-12-02
EP3106168A3 (en) 2017-02-22
EP2785355A1 (en) 2014-10-08
US20140323551A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
JP2015504847A (ja) 前立腺癌骨転移および薬剤耐性肺癌を治療するためのマイクロｒｎａｍｉｒ−４０９−５ｐ、ｍｉｒ−３７９、およびｍｉｒ−１５４＊の標的化
Wu et al. CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis
JP6807351B2 (ja) 診断及び治療のためのエクソソームにおけるｍｉＲＮＡバイオジェネシス
Gilles et al. Personalized RNA medicine for pancreatic cancer
ES2536907T3 (es) Métodos para determinar el subtipo de un carcinoma hepatocelular
Zhao et al. Up-regulation of the expressions of MiR-149-5p and MiR-99a-3p in exosome inhibits the progress of pituitary adenomas
WO2010091049A2 (en) Diagnosis and treatment of cancer
US20210369760A1 (en) Microrna-based therapy targeted against lcp-1 positive cancers
Geng et al. Targeting miR-9 in glioma stem cell-derived extracellular vesicles: a novel diagnostic and therapeutic biomarker
JP5931897B2 (ja) マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
WO2021052286A1 (zh) 新型外泌体释放相关靶点及其在监测和抑制肿瘤中的应用
Li et al. Long noncoding RNA AC114812. 8 promotes the progression of bladder cancer through miR-371b-5p/FUT4 axis
CN107586781B (zh) 肝癌标志物lncRNA ENST00000620463.1及其应用
Jiang et al. Low FAT4 expression is associated with a poor prognosis in gastric cancer patients
JP2016525874A (ja) ガンを治療するための療法のための標的として使用するためのｆａｌｚ
Nevskaya et al. Prevention of metastasis by suppression of stemness genes using a combination of microRNAs
US9745578B2 (en) Targeting microRNA miR-409-3P to treat prostate cancer
CN110251529A (zh) miR-124-3p与其类似物在制备抗乳腺癌疾病药物中的应用
Hussein et al. NEAT1: Culprit lncRNA linking PIG-C, MSLN, and CD80 in triple-negative breast cancer
Zhang et al. Non‐canonical RNA‐binding protein ANXA11 regulates microRNA resorting into small extracellular vesicles to mediate cisplatin resistance
CN106039312B (zh) Znf367基因在制备治疗乳腺癌药物、诊断及预后评估试剂中的应用
US9062308B2 (en) Compositions and methods for treatment of tamoxifen resistant breast cancer
US10835551B2 (en) Double-stranded nucleic acid molecule, DNA, vector, cancer cell growth inhibitor, cancer cell migration inhibitor, and drug
Shao et al. Upregulation of has_circ_0008389 promotes esophageal squamous cell carcinoma progression via miR-761 sponging and P2RY2 mRNA stabilization
Munyembaraga et al. MiR-493–3p suppresses the DPY-30 histone methyltransferase complex regulatory subunit to attenuate gefitinib resistance in lung cancer

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170301